Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Average Rating of “Moderate Buy” from Analysts

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $18.00.

Several research analysts have recently commented on TVRD shares. HC Wainwright initiated coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. BTIG Research cut their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday, July 8th. Finally, Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a research note on Wednesday, July 8th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TVRD. GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $34,000. Arax Advisory Partners lifted its holdings in shares of Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Finally, HRT Financial LP purchased a new position in shares of Tvardi Therapeutics during the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

Shares of Tvardi Therapeutics stock opened at $1.86 on Monday. Tvardi Therapeutics has a one year low of $1.50 and a one year high of $43.65. The company has a market cap of $24.81 million, a price-to-earnings ratio of -0.67 and a beta of 0.39. The business’s 50 day moving average price is $2.40 and its 200 day moving average price is $3.10.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.